QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=6786E3DFE84EB9E8E17DEF285DCC3349;jsessionid=0A67D1D8F60D4C29D9D57C3D1E5B147F;jsessionid=75EB2F945B93DBA803465299A6F10967;jsessionid=F5D115B93E2548548959ED66974630D1;jsessionid=C2B3702F5CE4811820D759EFF2EF56DD;jsessionid=798019EAB8D885E08F381CCBEA8B83D1;jsessionid=8200397B8F5C0E54C7E643919A6ACB31 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=6786E3DFE84EB9E8E17DEF285DCC3349;jsessionid=0A67D1D8F60D4C29D9D57C3D1E5B147F;jsessionid=75EB2F945B93DBA803465299A6F10967;jsessionid=F5D115B93E2548548959ED66974630D1;jsessionid=C2B3702F5CE4811820D759EFF2EF56DD;jsessionid=798019EAB8D885E08F381CCBEA8B83D1;jsessionid=8200397B8F5C0E54C7E643919A6ACB31